UK-based private equity firm Kester Capital has acquired EMAS Pharma, the clinical development division of Bionical Emas, alongside a new senior management team. Financial details of the transaction have not been disclosed. Headquartered in the UK, EMAS is a specialised, full-service global Clinical Research Organisation (CRO) offering expertise across multiple therapeutic areas, including oncology, rare…
Membership Required
You must be a HM Subscriber to view this content.
Already have an account? Sign In
©2025 All rights reserved LaingBuisson 
